VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
Dihydroartemisinin-piperaquine plus tafenoquine
Phase 3
Small molecule
S
Shoklo Malaria Research Unit
1
Indications
1
Total Trials
1
Active Trials
0
Competitors
Clinical
Trials by Indication
[1]
Infection
1 trial
ACT vs CQ With Tafenoquine for P. Vivax Mono-infection
Recruiting
·
S
Shoklo Malaria Research Unit
·
Phase 4
·
NCT05788094
·
606 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
1 trial record for Dihydroartemisinin-piperaquine plus tafenoquine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
Dihydroartemisinin-piperaquine plus tafenoquine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for Dihydroartemisinin-piperaquine plus tafenoquine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Shoklo Malaria Research Unit company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Phase 3
[1]
Company
S
Shoklo Malaria Research Unit
Related News